Afalase (Afalaza)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsp

lozenges

Composition:

For 1 tablet.

Active substances:

Antibodies to endothelial NO-initially purified synthase - 0.006 g. *

Antibodies to prostate-specific antigen affinity purified - 0.006 g. *

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* are applied to lactose in the form of a mixture of three active water-alcohol dilutions of the substance diluted 10012, 10030, 100200 time.

Description:

Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the flat side with the risk of inscription MATERIA MEDICA, on the other flat side there is an inscription AFALAZA.

Pharmacotherapeutic group:Prostate hyperplasia is a benign treatment tool
ATX: & nbsp
  • Drugs for the treatment of erectile dysfunction
    • Pharmacodynamics:

    Antibodies to prostate-specific antigen (PSA) affinity purified modify the functional activity of endogenous PSA, altered in benign prostatic hyperplasia, which is accompanied by an increase in the regulatory effect of this antigen on the functional and metabolic processes in the prostate tissue. Antibodies to PSA have a preventive and curative effect in prostate adenoma.

    Antibodies to endothelial NO synthase affinity purified contribute to an increase in the rate of blood flow in the vessels of the penis and prostate; has a protective effect in relation to the endothelium (contributes to a decrease in vascular reactivity, a reduction in vascular spasm, and improvement of peripheral microcirculation).

    Joint use of components in the complex preparation "Afalaza" is accompanied by a synergistic effect: antibodies to endothelial NO synthase due to endothelioprotective action and improved vascularization enhance the antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably also due to nonspecific mechanisms of amplification of intracellular transduction of the signal by dilutions of antibodies to endothelial NO synthase.

    Complex use of the components of the drug improves the quality of life of patients with benign prostatic hyperplasia (BPH) and prostatitis, reducing dysuric disorders and erectile dysfunction; has vegetative stabilizing effect.The presence of a pronounced anti-inflammatory and anti-edematous effect is experimentally demonstrated. The drug helps normalize the functional state of the prostate and lower urinary tract, improve urodynamics (decrease residual urine volume, increase the maximum urine rate), normalize the PSA level. The drug also contributes to the reduction of dysuric disorders, and in some cases to a moderate decrease in the volume of the prostate gland.

    Joint use of components improves spermatological parameters (increase in the concentration of sex hormones, the number of spermatozoa and their mobility, reduced viscosity of semen, normalization of the secretion of the prostate gland); activates regenerative-reparation processes in patients who underwent surgery for benign prostatic hyperplasia, reduces the likelihood of complications after surgery.

    Pharmacokinetics:

    The sensitivity of modern physical and chemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of active components preparation of Afalase in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics.

    Indications:

    Benign prostatic hyperplasia of the first and second stages.

    In the complex therapy of acute and chronic prostatitis - as an anti-inflammatory and analgesic.

    Dysuric disorders (frequent urination, difficulty with urination, pain and discomfort in the perineal region).

    Erectile dysfunction (erectile dysfunction) of various origin. Vegetative disorders of the climacteric period in men (weakness, fatigue, decreased physical activity, decreased libido, etc.).

    Complex therapy, used before and after surgical interventions on the prostate gland.

    Contraindications:

    Increased individual sensitivity to the components of the drug.

    Pregnancy and lactation:The drug Afalaza is not intended for use in women.
    Dosing and Administration:

    Inside. At one time - 2 tablets (keep in your mouth until completely dissolved - not during meals). The drug should be taken twice a day, in the evening and in the morning. The recommended duration of the drug is 16 weeks.

    With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, the drug is taken up to 4 times a day.

    If necessary, on the recommendation of a doctor, a repeat course of treatment can be performed after 1-4 months.

    Side effects:

    Possible reactions of increased individual sensitivity to the components of the drug.

    Overdose:

    In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.

    Interaction:

    Cases of incompatibility with other drugs to the present time is not registered.

    Special instructions:

    The composition of the drug includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

    Effect on the ability to drive transp. cf. and fur:

    Afalase does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

    Form release / dosage:Lozenges.
    Packaging:For 20 tablets in a planar cell pack of a polyvinyl chloride film or aluminum foil.For 1, 2 or 5 contour mesh packages together with the instruction for medical use are placed in a pack of cardboard.
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-006227/10
    Date of registration:01.07.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp20.09.2017
    Illustrated instructions
      Instructions
      Up